Related Experiment Video
Updated: Jul 10, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotic strategies for the secondary prevention of stroke: A review
Forough Yazdanian1, Luciano A Sposato2, Marc Fisher3
1Department of Medicine, Boston Medical Center South, Boston Medical Center Health System, Brockton, MA, USA.
Insights
Preventing recurrent ischemic stroke requires optimized antithrombotic therapy. Dual antiplatelet therapy (DAPT) is effective early, while direct oral anticoagulants (DOACs) benefit cardioembolic stroke patients.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Ischemic stroke affects over 600,000 annually in the U.S., with one-fourth being recurrent.
- Despite advances, recurrent strokes remain common, necessitating improved antithrombotic strategies to balance efficacy and safety.
Purpose of the Study:
- To review current antithrombotic strategies for preventing recurrent ischemic stroke and cardioembolic stroke.
- To discuss challenges in antithrombotic therapy, including adherence, risk stratification, and patient selection.
- To explore emerging strategies for optimizing antithrombotic treatment.
Main Methods:
- Review of clinical evidence on dual antiplatelet therapy (DAPT) for minor stroke/TIA.
- Analysis of data comparing direct oral anticoagulants (DOACs) with vitamin K antagonists for cardioembolic stroke.
- Discussion of novel antithrombotic agents and combination therapies.
Main Results:
- Early DAPT significantly reduces early ischemic stroke recurrence within 21 days (5.2% vs 7.8%).
- Beyond 21 days, DAPT's ischemic benefit diminishes while bleeding risk increases.
- DOACs demonstrate superior efficacy and safety compared to vitamin K antagonists for cardioembolic stroke (ischemic event OR 0.85, major bleeding OR 0.86).
Conclusions:
- Antithrombotic optimization for stroke prevention is complex.
- Emerging strategies like low-dose combinations and Factor XIa inhibitors show promise for reducing bleeding risk while maintaining efficacy.
Abstract:
Each year, over 600,000 ischemic strokes occur in the US, one-fourth of which are recurrent. Although preventive strategies have advanced, recurrent events remain common, highlighting the need for antithrombotic regimens that minimize ischemic and bleeding risks. In patients with minor ischemic stroke or high-risk Transient Ischemic Attack (TIA), early dual antiplatelet therapy (DAPT) followed by monotherapy significantly reduces early ischemic stroke recurrence, with greatest benefit within first 21 days (5.2% versus 7.8%; HR, 0.66; 95% CI, 0.56-0.77). Beyond this window, ischemic benefit diminishes and bleeding risk increases (0.3% versus 0.2%; HR, 1.28; 95% CI, 0.58-2.81). For cardioembolic stroke, particularly with atrial fibrillation, direct oral anticoagulants (DOACs) are favored over vitamin K antagonists, offering superior efficacy and safety (5.2% versus 5.9%; odds ratio [OR] 0.85; 95% CI, 0.74-0.99) and major bleeding (5.36% versus 6.16%; OR, 0.86; 95% CI, 0.78-0.99). However, antithrombotic optimization remains challenging-especially in adherence, risk stratification, and patient selection. Emerging strategies, including low-dose anticoagulant-antiplatelet combinations and Factor XIa inhibitors, aim to preserve antithrombotic benefit while reducing bleeding.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Atherosclerosis III: Management
01:29Venous Thrombosis III: Interprofessional Care
01:30Venous Thrombosis IV: Nursing Management